Compare HIW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | ARQT |
|---|---|---|
| Founded | 1978 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 1995 | 2020 |
| Metric | HIW | ARQT |
|---|---|---|
| Price | $30.61 | $31.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $31.89 | ★ $38.38 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | 54.26 | ★ 88.79 |
| EPS | ★ 0.29 | 0.03 |
| Revenue | ★ $806,112,000.00 | $376,072,000.00 |
| Revenue This Year | $6.94 | $43.01 |
| Revenue Next Year | $3.56 | $27.70 |
| P/E Ratio | ★ $105.16 | $1,071.67 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $20.45 | $19.30 |
| 52 Week High | $35.44 | $33.30 |
| Indicator | HIW | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 65.74 |
| Support Level | $30.11 | $23.42 |
| Resistance Level | $30.79 | N/A |
| Average True Range (ATR) | 0.86 | 1.58 |
| MACD | 0.20 | 0.61 |
| Stochastic Oscillator | 92.98 | 80.56 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.